DOP2013000132A - Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y bortezomib - Google Patents

Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y bortezomib

Info

Publication number
DOP2013000132A
DOP2013000132A DO2013000132A DO2013000132A DOP2013000132A DO P2013000132 A DOP2013000132 A DO P2013000132A DO 2013000132 A DO2013000132 A DO 2013000132A DO 2013000132 A DO2013000132 A DO 2013000132A DO P2013000132 A DOP2013000132 A DO P2013000132A
Authority
DO
Dominican Republic
Prior art keywords
bortezomib
antitumoral
specifically recognize
containing antibodies
combinations containing
Prior art date
Application number
DO2013000132A
Other languages
English (en)
Inventor
Pascale Lejeune
Michele F Mayo
Peter U Park
Jutta Deckert
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44168449&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2013000132(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of DOP2013000132A publication Critical patent/DOP2013000132A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composición farmacéutica que comprende un anticuerpo que reconoce específicamente CD38 y bortezomib.
DO2013000132A 2010-12-10 2013-06-10 Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y bortezomib DOP2013000132A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10306395 2010-12-10

Publications (1)

Publication Number Publication Date
DOP2013000132A true DOP2013000132A (es) 2013-09-30

Family

ID=44168449

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000132A DOP2013000132A (es) 2010-12-10 2013-06-10 Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y bortezomib

Country Status (41)

Country Link
US (1) US9314522B2 (es)
EP (2) EP2648747B1 (es)
JP (1) JP6177133B2 (es)
KR (1) KR101905208B1 (es)
CN (2) CN103282050B (es)
AR (1) AR084196A1 (es)
AU (1) AU2011340472B2 (es)
BR (1) BR112013014370B1 (es)
CA (1) CA2820382C (es)
CL (1) CL2013001670A1 (es)
CO (1) CO6801634A2 (es)
CR (1) CR20130270A (es)
CY (1) CY1121179T1 (es)
DK (1) DK2648747T3 (es)
DO (1) DOP2013000132A (es)
EA (2) EA201692047A1 (es)
EC (1) ECSP13012669A (es)
ES (1) ES2694784T3 (es)
GT (1) GT201300147A (es)
HR (1) HRP20181787T1 (es)
HU (1) HUE039893T2 (es)
IL (1) IL226756B (es)
LT (1) LT2648747T (es)
MA (1) MA34816B1 (es)
MX (1) MX345257B (es)
MY (1) MY165109A (es)
NI (1) NI201300050A (es)
NZ (1) NZ612055A (es)
PE (1) PE20140004A1 (es)
PL (1) PL2648747T3 (es)
PT (1) PT2648747T (es)
RS (1) RS57997B1 (es)
SG (2) SG10201600985XA (es)
SI (1) SI2648747T1 (es)
TN (1) TN2013000245A1 (es)
TR (1) TR201816532T4 (es)
TW (1) TWI596116B (es)
UA (1) UA112170C2 (es)
UY (1) UY33791A (es)
WO (1) WO2012076663A1 (es)
ZA (1) ZA201304845B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2191843A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
DK2621531T3 (en) 2010-09-27 2017-02-27 Morphosys Ag ANTI-CD38 ANTIBODY AND LENALIDOMIDE OR BORTEZOMIB FOR TREATMENT OF MULTIPLE MYELOM AND NHL
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
EP2900232B1 (en) 2012-09-25 2017-11-15 MorphoSys AG Combinations and uses thereof
AU2014244333B2 (en) * 2013-03-13 2019-02-07 Sanofi-Aventis U.S. Llc Compositions comprising anti-CD38 antibodies and carfilzomib
JP2016528221A (ja) * 2013-08-02 2016-09-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 抗クローディン１抗体およびその使用
NZ719784A (en) * 2013-10-31 2022-02-25 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers
SG10201913447SA (en) * 2013-10-31 2020-02-27 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US10617757B2 (en) 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
EP3191187B1 (en) 2014-09-09 2021-07-28 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
BR112017011749A2 (pt) 2014-12-04 2018-05-15 Janssen Biotech Inc anticorpos anti-cd38 para o tratamento de leucemia mieloide aguda
KR102602754B1 (ko) 2015-05-20 2023-11-14 얀센 바이오테크 인코포레이티드 경쇄 아밀로이드증 및 다른 cd38-양성 혈액학적 악성종양을 치료하기 위한 항-cd38 항체
MY192978A (en) 2015-06-22 2022-09-20 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
RS63210B1 (sr) 2015-11-03 2022-06-30 Janssen Biotech Inc Potkožne formulacije anti-cd38 antitela i njihova upotreba
CN117534754A (zh) 2017-06-08 2024-02-09 黑带医疗有限公司 Cd38调节抗体
SG11202000484TA (en) 2017-08-16 2020-02-27 Black Belt Therapeutics Ltd Cd38 antibody
US11542338B2 (en) 2017-08-16 2023-01-03 Black Belt Therapeutics Limited CD38 modulating antibody
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
WO2019089832A1 (en) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
WO2021113739A1 (en) 2019-12-05 2021-06-10 Thomas Ballet Formulations of anti-cd38 antibodies for subcutaneous administration

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB750155A (en) 1953-03-17 1956-06-13 Nat Res Dev Substituted alanines
US3032585A (en) 1954-12-03 1962-05-01 Nat Res Dev Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine
US3116282A (en) 1960-04-27 1963-12-31 Upjohn Co Pyrimidine nucleosides and process
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
KR100942002B1 (ko) 1996-12-03 2010-02-12 암젠 프레몬트 인코포레이티드 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린 유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된 항체
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
JP2003524587A (ja) 1998-06-05 2003-08-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用
DE19826517B4 (de) 1998-06-15 2006-03-23 Baxter Healthcare S.A. Verfahren zur Herstellung von Filmtabletten mit Cyclophosphamid als Wirkstoff und daraus hergestellte Cyclophosphamid-Filmtablette
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
GB0221574D0 (en) 2002-09-17 2002-10-23 Isis Innovation Treatments
SG142330A1 (en) 2004-02-06 2008-05-28 Morphosys Ag De Anti-cd38 human antibodies and uses therefor
JP4912597B2 (ja) 2004-07-13 2012-04-11 パナソニック株式会社 液晶表示装置
US20080057070A1 (en) 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
SI2567976T1 (sl) * 2005-03-23 2017-11-30 Genmab A/S Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma
EA034877B1 (ru) 2006-09-26 2020-04-01 Генмаб А/С Способ комбинированной терапии опухолей, экспрессирующих cd38, и терапевтическая комбинация для применения в указанном способе
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP3354662B1 (en) 2007-08-29 2020-08-19 Sanofi Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
CA2712989C (en) 2008-01-23 2015-10-27 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
EP2191841A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191842A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191840A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
DK2621531T3 (en) * 2010-09-27 2017-02-27 Morphosys Ag ANTI-CD38 ANTIBODY AND LENALIDOMIDE OR BORTEZOMIB FOR TREATMENT OF MULTIPLE MYELOM AND NHL
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
US8542056B2 (en) * 2010-12-27 2013-09-24 Stmicroelectronics S.Rl. High voltage transmission switch, namely for ultrasound applications
UA118255C2 (uk) 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
AU2014244333B2 (en) 2013-03-13 2019-02-07 Sanofi-Aventis U.S. Llc Compositions comprising anti-CD38 antibodies and carfilzomib
NZ719784A (en) 2013-10-31 2022-02-25 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers

Also Published As

Publication number Publication date
PL2648747T3 (pl) 2019-01-31
AU2011340472B2 (en) 2015-02-12
EA026406B1 (ru) 2017-04-28
KR20130130774A (ko) 2013-12-02
ECSP13012669A (es) 2013-08-30
PT2648747T (pt) 2018-11-21
HUE039893T2 (hu) 2019-02-28
EA201390850A1 (ru) 2013-12-30
TR201816532T4 (tr) 2018-11-21
EA201692047A1 (ru) 2017-06-30
CN103282050B (zh) 2016-09-07
EP2648747B1 (en) 2018-08-08
CR20130270A (es) 2013-09-03
CN103282050A (zh) 2013-09-04
SI2648747T1 (sl) 2019-04-30
JP2014502280A (ja) 2014-01-30
HRP20181787T1 (hr) 2018-12-28
ZA201304845B (en) 2014-09-25
IL226756B (en) 2020-06-30
CY1121179T1 (el) 2020-05-29
JP6177133B2 (ja) 2017-08-09
DK2648747T3 (en) 2018-12-03
US20140186337A1 (en) 2014-07-03
SG191059A1 (en) 2013-08-30
MA34816B1 (fr) 2014-01-02
EP2648747A1 (en) 2013-10-16
CN106334187A (zh) 2017-01-18
UY33791A (es) 2012-07-31
UA112170C2 (uk) 2016-08-10
TWI596116B (zh) 2017-08-21
EP3412311A1 (en) 2018-12-12
MX2013006566A (es) 2013-08-26
AU2011340472A1 (en) 2013-05-02
KR101905208B1 (ko) 2018-10-05
WO2012076663A1 (en) 2012-06-14
ES2694784T3 (es) 2018-12-27
CA2820382A1 (en) 2012-06-14
BR112013014370B1 (pt) 2020-12-01
PE20140004A1 (es) 2014-01-23
CN106334187B (zh) 2021-02-12
TN2013000245A1 (en) 2014-11-10
RS57997B1 (sr) 2019-01-31
CO6801634A2 (es) 2013-11-29
TW201307392A (zh) 2013-02-16
GT201300147A (es) 2017-12-15
US9314522B2 (en) 2016-04-19
NZ612055A (en) 2014-12-24
AR084196A1 (es) 2013-04-24
MY165109A (en) 2018-02-28
MX345257B (es) 2017-01-23
BR112013014370A2 (pt) 2017-05-30
CA2820382C (en) 2020-08-18
SG10201600985XA (en) 2016-03-30
LT2648747T (lt) 2018-11-26
NI201300050A (es) 2013-08-01
CL2013001670A1 (es) 2014-02-28

Similar Documents

Publication Publication Date Title
DOP2013000132A (es) Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y bortezomib
CR20110281A (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y vincristina
UY32263A (es) Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y melfalan
ECSP11011077A (es) Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y ciclofosfamida
CR20110282A (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y vincristina
TN2011000153A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide